{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:11Z","timestamp":1792716911623,"version":"4.5.0"},"reference-count":27,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Actinic keratosis (AK) is a common premalignant skin disorder associated with chronic ultraviolet exposure and a recognized risk of progression to cutaneous squamous cell carcinoma. Tirbanibulin 1% ointment is an effective short-course field therapy for AK, but its efficacy in hyperkeratotic lesions (Olsen grade II\u2013III) may be limited by reduced drug penetration through a thickened stratum corneum. Keratolytic pretreatment may represent a plausible strategy to improve topical drug delivery in these more challenging lesions. Methods: This retrospective chart review included consecutive adults with Olsen grade II\u2013III AK treated in routine clinical practice with either a bland emollient lead-in followed by tirbanibulin (Group A) or salicylic acid 30% ointment pre-treatment (Decapan, Sanitpharma; Milan, Italy) followed by tirbanibulin (Group B). No study-driven procedures or additional visits were implemented. The 14-day bland emollient lead-in used in Group A was part of the routine clinical management applied during the relevant treatment period and was not introduced or retrospectively constructed for the purposes of the present comparative analysis. Outcomes were extracted from de-identified medical records and photographic documentation obtained as part of standard care. For the purposes of analysis, post-treatment evaluations were grouped into predefined windows of 3\u20136 weeks (T1), 10\u201314 weeks (T2), and 22\u201330 weeks (T3), corresponding approximately to 1, 3, and 6 months after treatment initiation. The primary efficacy endpoints were the Actinic Keratosis Area and Severity Index (AKASI) and Total Lesion Count (TLC). Secondary endpoints included quality of life assessed by the Dermatology Life Quality Index (DLQI). Results: Both treatment regimens were associated with clinically meaningful improvements in AK severity. At T3, mean AKASI was significantly lower in Group B than in Group A (0.86 \u00b1 0.38 vs. 1.35 \u00b1 0.27; p &lt; 0.001), corresponding to reductions from baseline of 60.6% and 36.9%, respectively. Similarly, mean TLC at T3 was significantly lower in Group B than in Group A (4.80 \u00b1 1.5 vs. 6.35 \u00b1 1.6; p &lt; 0.001), corresponding to reductions from baseline of 46.7% and 27.0%, respectively. Quality-of-life outcomes also favored the sequential approach, with lower DLQI scores at T3 in Group B compared with Group A (2.9 \u00b1 1.6 vs. 3.8 \u00b1 1.9; p = 0.006). Both treatments were generally well tolerated. Although the incidence of local skin reactions (LSRs) was similar between groups, Group B showed lower retrospectively documented composite LSR scores and lower patient-reported discomfort (p &lt; 0.001) and lower patient-reported discomfort (p &lt; 0.001). Conclusions: Sequential keratolytic pretreatment followed by tirbanibulin was associated with greater reductions in disease burden and with lower severity of treatment-related local reactions in this retrospective cohort (Olsen grade II\u2013III). This retrospective study suggests that keratolytic pretreatment may represent a useful adjunctive strategy in hyperkeratotic AK treated with tirbanibulin. Prospective randomized studies are warranted to confirm these findings and to define standardized treatment protocols.<\/jats:p>","DOI":"10.3390\/ph19060954","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:06:34Z","timestamp":1782875194000},"page":"954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential Keratolytic Pre-Treatment Followed by Tirbanibulin in Hyperkeratotic Actinic Keratoses: A Retrospective Comparative Study"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3795-3190","authenticated-orcid":false,"given":"Ilaria","family":"Proietti","sequence":"first","affiliation":[{"name":"Dermatology Unit \u00abDaniele Innocenzi\u00bb, Alfredo Fiorini Hospital, 04019 Terracina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8346-8359","authenticated-orcid":false,"given":"Vincenzo","family":"Coppolelli","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0811-7601","authenticated-orcid":false,"given":"Alberto","family":"Taliano","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2788","authenticated-orcid":false,"given":"Alessandro","family":"Colletti","sequence":"additional","affiliation":[{"name":"Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cantisani","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u00abDaniele Innocenzi\u00bb, Alfredo Fiorini Hospital, 04019 Terracina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","article-title":"Actinic keratoses: Review of clinical, dermoscopic, and therapeutic aspects","volume":"94","author":"Reinehr","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2013.134","article-title":"Prevalence of actinic keratosis and its risk factors in the general population: The Rotterdam Study","volume":"133","author":"Flohil","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1753-6405.12470","article-title":"Cancers in Australia attributable to exposure to solar ultraviolet radiation and prevented by regular sunscreen use","volume":"39","author":"Olsen","year":"2015","journal-title":"Aust. N. Z. J. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.07021.x","article-title":"A population-based study of skin cancer incidence and prevalence in renal transplant recipients","volume":"154","author":"Moloney","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","article-title":"A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions","volume":"23","author":"Catapano","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Arcuri, D., Ramchatesingh, B., Lagac\u00e9, F., Iannattone, L., Netchiporouk, E., Lefran\u00e7ois, P., and Litvinov, I.V. (2023). Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054989"},{"key":"ref_7","first-page":"S3","article-title":"Profile of Tirbanibulin for the Treatment of Actinic Keratosis","volume":"15","author":"Berman","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19913s13","DOI":"10.36849\/JDD.19913","article-title":"Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis","volume":"24","author":"Roberts","year":"2025","journal-title":"J. Drugs Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Dykukha, I., Graziadio, S., Salido-Vallejo, R., Chapman-Rounds, M., and Edwards, M. (2022). Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061654"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/jdv.12530","article-title":"Physician perceptions and experience of current treatment in actinic keratosis","volume":"29","author":"Stockfleth","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","article-title":"Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis","volume":"49","author":"Flohil","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.36849\/JDD.8264","article-title":"Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)","volume":"23","author":"Schlesinger","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized Trial of Four Treatment Approaches for Actinic Keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/bjd.12591","article-title":"Reliability of Quantification Measures of Actinic Keratosis","volume":"169","author":"Chen","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjd.12036","article-title":"Assessing the Influence of Actinic Keratosis on Patients\u2019 Quality of Life: The AKQoL Questionnaire","volume":"168","author":"Esmann","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-021-01479-0","article-title":"Tirbanibulin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/CCID.S84765","article-title":"Salicylic acid as a peeling agent: A comprehensive review","volume":"8","author":"Arif","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0068-3","article-title":"Keratolytics and Emollients and Their Role in the Therapy of Psoriasis: A Systematic Review","volume":"5","author":"Jacobi","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100534","DOI":"10.1016\/j.conctc.2020.100534","article-title":"Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial","volume":"17","author":"Redzic","year":"2020","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.15107","article-title":"British Association of Dermatologists\u2019 Guidelines for the Care of Patients with Actinic Keratosis 2017","volume":"176","author":"McGregor","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/2229-5178.209622","article-title":"Topical Therapies in Psoriasis","volume":"8","author":"Orsekar","year":"2017","journal-title":"Indian Dermatol. Online J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jdv.14267","article-title":"A proposed scoring system for assessing the severity of actinic keratosis on the head: Actinic keratosis area and severity index","volume":"31","author":"Dirschka","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: A comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Campione, E., Rivieccio, A., Gaeta Shumak, R., Costanza, G., Cosio, T., Lambiase, S., Garofalo, V., Artosi, F., Lozzi, F., and Freni, C. (2023). Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121686"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19912s5","DOI":"10.36849\/JDD.19912","article-title":"Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and Patient-Reported Outcomes","volume":"24","author":"Jeong","year":"2025","journal-title":"J. Drugs Dermatol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:27:25Z","timestamp":1782876445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060954"],"URL":"https:\/\/doi.org\/10.3390\/ph19060954","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}